Tresiba Injection, Solution
Product Images NDC 0169-2662

65 FDA label images from Novo Nordisk · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 65 technical images submitted to the FDA as part of the official labeling for Tresiba (NDC 0169-2662). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Novo Nordisk, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure 1: Structural Formula Of Tresiba (Image 01)

Figure 1: Structural Formula Of Tresiba (Image 01)
Chemical structure diagram of insulin degludec, illustrating its amino acid sequence from A1 to A29 and B1 to B29 with a fatty acid side chain attached to the B20 position.*
FDA Label Image

Figure 2: Mean Gir Profile For 0.4 U/kg Dose Of Tresiba (steady State) In Patients With Type 1 Diabetes Mellitus (Image 02)

Figure 2: Mean Gir Profile For 0.4 U/kg Dose Of Tresiba (steady State) In Patients With Type 1 Diabetes Mellitus (Image 02)
A line graph showing the glucose infusion rate (GIR) over time in hours since injection for insulin degludec at a dose of 0.4 U/kg. The x-axis represents time in hours, and the y-axis represents GIR. A shaded area on the graph highlights the 24-hour interval after injection.*
FDA Label Image

Figure A: Novofine Needle Components (Image 03)

Figure A: Novofine Needle Components (Image 03)
An illustration shows a vial labeled with a tamper-resistant cap featuring a rubber stopper under the cap. The vial is intended for subcutaneous injection solution form, as used with insulin products like Tresiba.*
FDA Label Image

Figure A: Novotwist Needle Components (Image 04)

Figure A: Novotwist Needle Components (Image 04)
Illustration showing a hand holding a small vial, likely representing the vial form of Tresiba (insulin degludec) injection, solution for subcutaneous use. The image emphasizes the vial size and handling.*
FDA Label Image

Figure A: Tresiba Flextouch Pen Components (Image 05)

Figure A: Tresiba Flextouch Pen Components (Image 05)
Instructional illustration showing a hand using a vial adapter or similar device to connect two components, likely part of the preparation or administration process for the Tresiba injection solution. The diagram includes two outlined panels depicting sequential steps of attachment.*
FDA Label Image

Figure A: Novofine Needle Components (Image 06)

Figure A: Novofine Needle Components (Image 06)
An instructional illustration showing how to attach a needle to a syringe. The diagram depicts hands holding the syringe and needle, with an arrow indicating the needle being pushed onto the syringe tip. A smaller inset shows the needle separately for clarity.*
FDA Label Image

Figure A: Novotwist Needle Components (Image 07)

Figure A: Novotwist Needle Components (Image 07)
An instructional illustration showing a hand holding a Tresiba injection pen, with the other hand pulling off a cap from the needle. This depicts preparation steps for subcutaneous administration of Tresiba (insulin degludec) injection, solution.*
FDA Label Image

100 U/ml Ifu (Figure B)

100 U/ml Ifu (Figure B)
An instructional illustration showing a hand holding a pen-shaped injection device and another hand twisting or removing the cap from the needle, indicating preparation steps for subcutaneous injection with Tresiba insulin degludec.*
FDA Label Image

100 U/ml Ifu (Figure C)

100 U/ml Ifu (Figure C)
An instructional illustration showing a hand holding a syringe or pen device, with the other hand pulling a cap or protective cover downward, indicated by a downward arrow. This diagram demonstrates a step in the preparation or use of an injection.*
FDA Label Image

100 U/ml Ifu (Figure D)

100 U/ml Ifu (Figure D)
Illustration showing a hand holding a Tresiba injection pen (insulin degludec) to be used for subcutaneous injection. The image depicts proper handling of the injection device before administration.*
FDA Label Image

100 U/ml Ifu (Figure E)

100 U/ml Ifu (Figure E)
An instructional diagram showing hands removing a cap from an injection pen for subcutaneous administration. A close-up inset highlights the twist-off action on the pen cap, illustrating preparation for insulin injection.*
FDA Label Image

100 U/ml Ifu (Figure F)

100 U/ml Ifu (Figure F)
An instructional illustration showing the proper technique for drawing Tresiba (insulin degludec) injection solution from a vial. It depicts a hand holding the vial upright and another hand inserting a syringe needle into the vial, indicated by an arrow to guide correct needle placement.*
FDA Label Image

100 U/ml Ifu (Figure G)

100 U/ml Ifu (Figure G)
An instructional illustration showing recommended subcutaneous injection sites on the human body, including the abdomen, front and outer thighs, and upper buttocks. The diagrams depict a front and back view of a human figure with shaded areas indicating these injection sites.*
FDA Label Image

100 U/ml Ifu (Figure H)

100 U/ml Ifu (Figure H)
An instructional diagram showing a person administering a subcutaneous injection in the forearm using a pen device. The illustration highlights the injection technique with an arrow indicating the insertion of the needle into the skin, relevant for the use of Tresiba (insulin degludec) injection.*
FDA Label Image

100 U/ml Ifu (Figure I)

100 U/ml Ifu (Figure I)
An instructional illustration showing the use of a syringe or injection device for subcutaneous administration, depicting a hand holding the device and an arrow indicating upward motion from the injection site on the skin, likely demonstrating injection technique or needle removal.*
FDA Label Image

100 U/ml Ifu (Figure J)

100 U/ml Ifu (Figure J)
An instructional diagram labeled NovoFine depicting the parts of a needle assembly for injection: an outer needle cap, an inner needle cap, the needle itself, and a paper tab.*
FDA Label Image

100 U/ml Ifu (Figure K)

100 U/ml Ifu (Figure K)
Illustration showing components of a NovoTwist pen needle device, including the outer needle cap, inner needle cap, needle, and paper tab, used for subcutaneous injection with Tresiba insulin degludec.*
FDA Label Image

100 U/ml Ifu (Figure L)

100 U/ml Ifu (Figure L)
An instructional diagram of the Tresiba FlexTouch insulin pen for subcutaneous injection. The labeled components include pen cap, insulin scale, insulin window, dose counter, dose selector, dose pointer, and dose button. The pen is shown in a horizontal layout with the injection end on the left and the dose button on the right.*
FDA Label Image

100 U/ml Ifu (Figure M)

100 U/ml Ifu (Figure M)
An instructional illustration showing a person's hands removing or peeling back a protective seal or label from a cylindrical injection device, likely related to the administration of Tresiba (insulin degludec) injection solution.*
FDA Label Image

100 U/ml Ifu (Figure N)

100 U/ml Ifu (Figure N)
An instructional illustration showing a hand holding a Tresiba injection pen horizontally, presumably demonstrating its proper use or handling. The image highlights the pen's capped needle area and thumb dial mechanism without additional text or instructions.*
FDA Label Image

100 U/ml Ifu (Figure O)

100 U/ml Ifu (Figure O)
An instructional illustration labeled Figure D showing how to use NovoFine and NovoTwist needles. It depicts fingers holding the needle with arrows indicating the direction to pull or twist for removal or attachment, related to the administration of subcutaneous injections.*
FDA Label Image

100 U/ml Ifu (Figure P)

100 U/ml Ifu (Figure P)
An instructional illustration showing the use of NovoFine and NovoTwist needle devices. The image demonstrates a hand holding a pen needle with arrows indicating the twisting action required for attachment or removal, relevant for subcutaneous injection of Tresiba insulin degludec.*
FDA Label Image

100 U/ml Ifu (Figure Q)

100 U/ml Ifu (Figure Q)
An instructional illustration showing the connection of a NovoFine needle or a NovoTwist needle to an injection device. The image includes directional arrows indicating how to attach the needle components properly for subcutaneous injection using Tresiba (insulin degludec) injection.*
FDA Label Image

100 U/ml Ifu (Figure R)

100 U/ml Ifu (Figure R)
An instructional illustration showing two steps for using a medical injection device. The first panel shows detaching a needle cover; the second panel shows removing a blue cap from the needle area. The image is labeled with NovoFine and NovoTwist, brand names associated with injection needles.*
FDA Label Image

100 U/ml Ifu (Figure S)

100 U/ml Ifu (Figure S)
An instructional diagram showing a close-up of hands adjusting a dose dial on a Tresiba insulin injection pen, with a display indicating a selection of 2 units. The image illustrates how to select the insulin dose for subcutaneous injection with Tresiba 100 U/mL or 200 U/mL insulin degludec solution by Novo Nordisk.*
FDA Label Image

100 U/ml Ifu (Figure T)

100 U/ml Ifu (Figure T)
An illustration showing a hand pressing or activating the top of a Tresiba insulin degludec injection pen. The image depicts the pen in a vertical orientation, highlighting user interaction to prepare for subcutaneous injection.*
FDA Label Image

Qr Code 100 Units/ml (Image 27)

Qr Code 100 Units/ml (Image 27)
An instructional illustration showing a hand holding a Tresiba insulin degludec injection pen. The image highlights pressing a button or knob at the pen's bottom with an upward arrow indicating a step in the injection preparation or dose setting process.*
FDA Label Image

Cover Page: Tresiba Flextouch 100 Units/ml (Image 28)

Cover Page: Tresiba Flextouch 100 Units/ml (Image 28)
An instructional illustration showing a dosage dial on a Tresiba insulin pen. It depicts selecting units for injection, with examples of 5 units and 24 units displayed on the dial, indicating how to set the dose by turning the pen dial upward.*
FDA Label Image

Figure A: Tresiba Flextouch U200 Pen Components (Image 29)

Figure A: Tresiba Flextouch U200 Pen Components (Image 29)
An instructional illustration depicting an insulin pen cartridge, showing an example of approximately 200 units remaining. The image highlights the cartridge's fill level visible through its transparent section with dosage markings on the side, consistent with subcutaneous injection preparation for insulin delivery.*
FDA Label Image

200 U/ml Ifu Figure B (Image 30)

200 U/ml Ifu Figure B (Image 30)
An instructional anatomical illustration showing front and back views of a human body with recommended subcutaneous injection sites highlighted. The areas include the abdomen, upper arms, front and outer thighs, and buttocks.*
FDA Label Image

200 U/ml Ifu Figure C (Image 31)

200 U/ml Ifu Figure C (Image 31)
An instructional illustration showing a hand holding a pen-like injection device vertically with the needle pointing downward, indicating to push or move the device downward as part of the injection process. No text or brand information is visible in the image.*
FDA Label Image

200 U/ml Ifu Figure D (Image 32)

200 U/ml Ifu Figure D (Image 32)
An instructional illustration showing a hand holding a pen-style injection device for insulin degludec (Tresiba). The diagram demonstrates pressing the injection button down into the skin to administer the subcutaneous injection.*
FDA Label Image

200 U/ml Ifu Figure E (Image 33)

200 U/ml Ifu Figure E (Image 33)
An instructional illustration showing a hand holding a small vial or pen device. The hand slowly counts from 1 to 6, indicated in a speech bubble, likely demonstrating how to prepare or administer a dose slowly. No specific product branding or text is visible in this image.*
FDA Label Image

200 U/ml Ifu Figure F (Image 34)

200 U/ml Ifu Figure F (Image 34)
An instructional diagram showing a close-up of an injection pen with an arrow pointing upward, illustrating the step of pulling or removing the cap from the pen before use. The background is light blue with a caption labeled Figure Q.*
FDA Label Image

200 U/ml Ifu Figure G (Image 35)

200 U/ml Ifu Figure G (Image 35)
An instructional illustration showing the use of NovoFine and NovoTwist injection needles. The image demonstrates how to attach or remove the needle with directional arrows pointing right for NovoFine and upward for NovoTwist against a light green background.*
FDA Label Image

200 U/ml Ifu Figure H (Image 36)

200 U/ml Ifu Figure H (Image 36)
An instructional diagram showing a close-up of a pen needle attachment process. The image depicts a pen needle being aligned and pushed onto the end of an injection pen, indicated by arrows guiding the assembly.*
FDA Label Image

200 U/ml Ifu Figure I (Image 37)

200 U/ml Ifu Figure I (Image 37)
An instructional illustration showing hands manipulating a component, likely a cap or ring, indicating a twisting or removal action. The image is simple, using blue and white colors with a yellow highlight on the part being handled.*
FDA Label Image

200 U/ml Ifu Figure J (Image 38)

200 U/ml Ifu Figure J (Image 38)
FDA Label Image

200 U/ml Ifu Figure K (Image 39)

200 U/ml Ifu Figure K (Image 39)
An instructional diagram of a Tresiba FlexTouch insulin pen for subcutaneous injection. The labeled components include the pen cap, insulin scale, insulin window, dose counter, dose selector, and the Tresiba label showing the 200 units/mL strength.*
FDA Label Image

200 U/ml Ifu Figure L (Image 40)

200 U/ml Ifu Figure L (Image 40)
An illustrated diagram labeled 'NovoFine' showing the components of a needle assembly. It includes the outer needle cap, inner needle cap, needle, and paper tab arranged from left to right, representing parts of a subcutaneous injection needle system used with insulin products.*
FDA Label Image

200 U/ml Ifu Figure M (Image 41)

200 U/ml Ifu Figure M (Image 41)
An instructional diagram labeled 'NovoTwist' showing the components of a needle system for subcutaneous injection. It depicts the outer needle cap, inner needle cap, needle, and a paper tab, each separately illustrated from left to right.*
FDA Label Image

200 U/ml Ifu Figure N (Image 42)

200 U/ml Ifu Figure N (Image 42)
Tresiba (insulin degludec) injection 100 units/mL (U-100) in a 10 mL multiple-dose vial for subcutaneous use. The label includes dosage strength, administration route, manufacturer Novo Nordisk, and a barcode. It also contains storage instructions and use warnings.*
FDA Label Image

200 U/ml Ifu Figure O (Image 43)

200 U/ml Ifu Figure O (Image 43)
An instructional illustration depicting two hands manipulating a pen-like device. One hand grips the device while the other hand appears to be pulling off or attaching a cap or protective cover at the end of the device, possibly a medication injection pen.*
FDA Label Image

200 U/ml Ifu Figure P (Image 44)

200 U/ml Ifu Figure P (Image 44)
An instructional illustration showing a close-up of a component of a Tresiba insulin injection pen. It depicts part of the pen with a focus on the dosage window or dose selector mechanism used to set the insulin dose before subcutaneous administration.*
FDA Label Image

200 U/ml Ifu Figure Q (Image 45)

200 U/ml Ifu Figure Q (Image 45)
An instructional illustration showing hands operating NovoFine and NovoTwist injection needles. The image demonstrates how to remove needle caps by pulling and twisting, with arrows indicating the direction of movement for safe preparation of an insulin injection.*
FDA Label Image

200 U/ml Ifu Figure R (Image 46)

200 U/ml Ifu Figure R (Image 46)
An instructional illustration showing the use of a NovoFine and NovoTwist needle for injecting Tresiba (insulin degludec) injection. The two-panel image demonstrates how to attach and twist the needle onto the insulin pen device.*
FDA Label Image

200 U/ml Ifu Figure S (Image 47)

200 U/ml Ifu Figure S (Image 47)
Instructional diagram showing the connection process between a NovoFine needle and a NovoTwist pen injector for subcutaneous insulin administration. The illustration highlights inserting and securing the needle on the pen.*
FDA Label Image

200 U/ml Ifu Figure T (Image 48)

200 U/ml Ifu Figure T (Image 48)
Illustration diagram showing the use of NovoFine and NovoTwist needles designed for subcutaneous injection of Tresiba (insulin degludec). The images depict the process of preparing the needle for injection, highlighting steps involved in removing or attaching components.*
FDA Label Image

Qr Code 200 Units/ml Ifu (Image 49)

Qr Code 200 Units/ml Ifu (Image 49)
An instructional illustration showing the dosing dial of a Tresiba insulin degludec injection pen. The image demonstrates selecting 2 units of dosage on the dial, with a close-up window displaying "2" units. Two hands are shown adjusting the dial, with an arrow indicating the turning direction.*
FDA Label Image

U-100 (Image 50)

U-100 (Image 50)
Tresiba FlexTouch 100 units/mL injection packaging label for insulin degludec by Novo Nordisk. The label shows a 5 mL prefilled pen for subcutaneous injection with directions and warnings about changing insulin. The label includes images of the pen device, barcodes, and references to multiple registered trademarks by Novo Nordisk.*
FDA Label Image

U-200 (Image 51)

U-200 (Image 51)
Tresiba FlexTouch insulin degludec injection 200 units/mL subcutaneous solution packaging label by Novo Nordisk. The label includes brand and generic names, dosage form, route, strength, and manufacturer details, with images of the pen injector device and usage warnings. The design also features Novo Nordisk logos and barcodes.*
FDA Label Image

Figure 3 (Image 52)

Figure 3 (Image 52)
A Kaplan-Meier curve comparing the cumulative percentage of subjects experiencing an event over 30 months for insulin degludec (IDeg) and insulin glargine (IGlar). The x-axis represents time to first event in months, and the y-axis shows the percentage of subjects with an event. The graph includes hazard ratio data (0.91 with 95% CI of 0.78 to 1.06).*
FDA Label Image

Image 53

Image 53
An instructional illustration showing a hand holding and shaking or mixing a vial or pen device, likely related to preparing an injection. The image highlights the motion with curved lines near the vial and finger.*
FDA Label Image

Image 54

Image 54
An illustration showing a hand holding a Tresiba injection pen vertically with the dose selector knob being pulled upward. A close-up inset highlights the mechanism for attaching the pen needle to the injection pen.*
FDA Label Image

Image 55

Image 55
An instructional illustration showing the dosage selection on a Tresiba insulin injection pen by Novo Nordisk. It depicts a hand adjusting the dial to select doses of 6 units and 24 units on the dose selector, with numerical examples visible in the display window.*
FDA Label Image

Image 56

Image 56
An illustration of a syringe or pen injector showing a vertical view with measurement markings for units, highlighting an approximate dose of 400 units left in the cartridge or reservoir. Details suggest it is related to dosing insulin, likely Tresiba (insulin degludec) injection.*
FDA Label Image

Image 57

Image 57
An anatomical illustration showing the recommended subcutaneous injection sites for Tresiba (insulin degludec) on the front and back of a human body. Highlighted injection areas include the abdomen, upper thighs, and upper outer arms.*
FDA Label Image

Image 58

Image 58
An instructional illustration showing a hand holding a pen-style injection device for subcutaneous administration. The hand grips the device with the thumb pressing down on the top, accompanied by a downward-pointing arrow below, indicating the direction to press or inject. The image is labeled as Figure N.*
FDA Label Image

Image 59

Image 59
An instructional diagram showing a hand holding an injection pen with an arrow pointing downward toward the injection site on the skin in the forearm area. To the left is an inset image showing a dial set to number 3, likely indicating a step in the injection process.*
FDA Label Image

Image 60

Image 60
An instructional illustration showing a hand holding an insulin pen and counting slowly from 1 to 6. The image likely demonstrates proper technique or timing for using the injection device for the medication Tresiba (insulin degludec).*
FDA Label Image

Image 61

Image 61
An instructional illustration depicting a subcutaneous insulin injection pen with an arrow pointing upwards, indicating the direction for removing or attaching the cap or needle.*
FDA Label Image

Image 62

Image 62
An instructional illustration demonstrating two different mechanisms labeled 'NovoFine' and 'NovoTwist' for needle attachment or removal on a syringe or pen device. The diagrams show a hand manipulating the device with arrows indicating the direction for detaching or attaching the needle component.*
FDA Label Image

Image 63

Image 63
An instructional diagram showing the assembly or connection of a syringe or pen needle to an injection device. The illustration features arrows indicating the direction for attaching the needle cap to the device.*
FDA Label Image

Image 64

Image 64
Instructional illustration showing hands twisting and removing a green cap or protective cover from a small cylindrical object, likely part of an injection device.*
FDA Label Image

Image 65

Image 65

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.